Protara Therapeutics, Inc. (TARA) company profile
Close on Nov 17, 2026Market cap $137.10MP/E –Yield –
About Protara Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its pipeline includes TARA-002, an investigational cell therapy being developed for non-muscle invasive bladder cancer and lymphatic malformations. The company is also developing intravenous choline chloride, a phospholipid substrate replacement therapy intended for adolescent and adult patients dependent on parenteral support when oral or enteral nutrition is not possible, insufficient, or contraindicated. Its intended customer base comprises patients with these oncologic and rare disease conditions who have limited treatment options.
The company operates primarily in the United States and has clinical trials and studies spanning the United States, the United Kingdom, and Europe. It holds worldwide development and commercialization rights to TARA-002, excluding Japan and Taiwan. Protara Therapeutics maintains its corporate headquarters at 345 Park Avenue South in New York, New York.
Summary of the business section of Protara Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Protara Therapeutics, Inc.
- Founded
- 2001
- Headquarters
- New York, NY
- Address
- 345 Park Avenue South, 3rd Floor 10010
- Phone
- (646) 844-0337
- Website
- www.proteontherapeutics.com
- Employees
- 51, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, New York
Stock & identifiers
- Ticker
- TARA
- Former tickers
- PRTO until Mar 20, 2020
- Exchange
- Nasdaq
- IPO date
- Oct 22, 2014
- Shares outstanding
- 59M, Aug 7, 2026
- Public float
- $112.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-40 reverse, Jan 10, 2020
- SEC CIK
- 1359931
- CUSIP
- 74365U107
- ISIN
- US74365U1079
- FIGI
- BBG001ZLYSH5
- Share class FIGI
- BBG001ZLYSK1
- LEI
- 549300VWUGH3220TG273
- EIN
- 20-4580525
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jesse Shefferman | CEO and President, Director | 1,007,832 |
| William Conkling | Chief Commercial Officer | 69,992 |
| Jacqueline Zummo | Chief R&D Officer | 94,827 |
| Hannah Fry | VP, Controller | 42,723 |
| Patrick Fabbio | Chief Financial Officer | 64,115 |
| Leonardo Viana Nicacio | Chief Medical Officer | 78,181 |
| Cynthia Smith | Director | – |
| Michael Edward Solomon | Director | 26,500 |
| Gregory Sargen | Director | 31,000 |
| Roger Garceau | Director | 33,000 |
| Jane Huang | Director | – |
| Luke M. Beshar | Director | 198,000 |
| Barry P. Flannelly | Director | – |
| Richard S. Levy | Director | 51,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $2.66M | $2.31M | $1.38M | $199 | – |
| FY2024 | $1.79M | $4.39M | $1.11M | $197 | – |
| FY2023 | $1.91M | $1.27M | $1.24M | $70 | – |
| FY2022 | $2.78M | $1.01M | $1.29M | $11 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Jesse Shefferman President, Chief Executive Officer and Director | $654.89K | – | $294.45K | $1.28M | $351.18K | $78.04K | $2.66M | +48% |
| Leonardo Nicacio, M.D. Chief Medical Officer | $373.86K | $75.00K | $208.50K | $453.44K | $229.75K | $41.93K | $1.38M | – |
| Jacqueline Zummo, Ph.D. Chief R&D Officer (6) | $494.00K | – | $110.99K | $481.84K | $219.52K | $75.92K | $1.38M | +14% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 22, 2014
- Offer price
- $10.00
- Securities offered
- 6,110,000
- Gross proceeds
- $61.10M
- Exchange
- Nasdaq
- First trading day
- Oct 22, 2014
- First-day close
- $10.03+0.3%
- Lock-up ends (est.)
- Apr 20, 2015
“Per Share Total Initial public offering price $ 10.00 $ 61,100,000 Underwriting discount and commissions(1) $ 0.70 $ 4,277,000 Proceeds, before expenses, to us $ 9.30 $ 56,823,000 (1) We have agreed to reimburse the underwriters for certain expenses.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“we had 51 employees, 46 of whom were full-time employees and five of whom were temporary employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 17, 2021 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Apr 23, 2020 | Name change | Name changed from ArTara Therapeutics, Inc. to Protara Therapeutics, Inc. |
| Mar 23, 2020 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jan 10, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 31, 2019 | Name change | Name changed from PROTEON THERAPEUTICS INC to ArTara Therapeutics, Inc. |
| Nov 7, 2019 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Oct 10, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 15, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 15, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 22, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 16, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?